This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. (Dialog)

This study is currently recruiting participants.
See Contacts and Locations
Verified May 2017 by Novartis ( Novartis Pharmaceuticals )
Sponsor:
Collaborators:
Children's Oncology Group
Innovative Therapies For Children with Cancer Consortium
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01844765
First received: April 29, 2013
Last updated: May 25, 2017
Last verified: May 2017
  Purpose
To evaluate the safety, efficacy and concentration of nilotinib over time in the Ph+ chronic myelogenous leukemia (CML) in pediatric patients (from 1 to <18 years).

Condition Intervention Phase
Leukemia Leukemia,Pediatric Leukemia, Myleiod Leukemia, Mylegenous, Chronic Leukemia, Mylegenous, Accelerated BCR-ABL Positive Myeloproliferative Disorder Bone Marrow Disease Hematologic Diseases Neoplastic Processes Imatinib Dasatinib Enzyme Inhibitor Protein Kinase Inhibitor Drug: nilotinib Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Multi-center, Open Label, Non-controlled Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Ph+ Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) or With Ph+ CML in CP or Accelerated Phase (AP) Resistant or Intolerant to Either Imatinib or Dasatinib

Resource links provided by NLM:


Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Rate of Major Molecular Responder (MMR) by BCR-ABL RQ-PCR analysis from peripheral blood by 12 cycles [ Time Frame: 12 cycles ]
    Newly diagnosed Ph+ CML chronic phase (CP) patients will be counted as Major Molecular Responder (MMR) by 12 cycles if the MMR criteria is achieved at least once any time between first study drug intake and cycle 12 visit.

  • Rate of CCyR at 12 cycles [ Time Frame: 12 cycles ]
    Newly diagnosed Ph+ CML-CP patients will be counted as Complete Cytogenetic Responder (CCyR) at 12 cycles if CCyR criteria is achieved at cycle 12 visit.

  • Rate of Major Molecular Responder (MMR) by BCR-ABL RQ-PCR analysis from peripheral blood at 6 cycles [ Time Frame: 6 cycles ]
    Resistant/intolerant Ph+ CML CP patients will be counted as Major Molecular Responder (MMR) at 6 cycles if the MMR criteria is achieved at cycle 6 visit.

  • Rate of Confirmed Hematological Responder (CHR) measured by complete blood count by 3 cycles [ Time Frame: 3 cycles ]
    Resistant/intolerant Ph+ CML advanced phase (AP) patients will be counted as Complete Hematological Responder (CHR) by 3 cycles if the CHR criteria is achieved at least once anytime between first study drug intake and cycle 3 visit.


Secondary Outcome Measures:
  • Time to response [ Time Frame: up to 66 cycles ]
    Time to response is defined as the time from the date of first study drug intake to the date of the first specified response.

  • Duration of response [ Time Frame: up to 66 cycles ]
    Duration of a response is defined as the time between the date of the first specified response to either the date for confirmed loss of the response or progression to advance phase (AP)/BC (from CP) or to BC (from AP) or CML-related death, whichever is earlier.

  • Time to Disease Progression [ Time Frame: up to 66 cycles ]
    Time to disease progression is defined as the time from the date of first study drug intake to the date of the event defined as the first progression to AP/BC (from CP) or to BC (from AP) or the date of CML-related death, whichever is earlier.

  • Overall survival (OS) [ Time Frame: up to 66 cycles ]
    Overall survival is defined as the time from the date of first study drug intake to the date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of their last assessment for patients on study and date of last contact for patients in follow-up.

  • Rate of major cytogenetic response (MCyR) and confirmed cytogenetic response (CCyR) in Newly diagnosed Ph+ CML and in Ph+ CML-AP patients resistant/intolerant to either imatinib or dasatinib [ Time Frame: 6, 12, 18, 24, 36, 48, 66 cycles ]
    Rate of major cytogenetic response (MCyR) and confirmed cytogenetic response (CCyR) in Newly diagnosed Ph+ CML and in Ph+ CML-AP patients resistant/intolerant to either imatinib or dasatinib by designated timepoints

  • Pharmacodynamics [ Time Frame: up to 66 cycles ]
    BCR-ABL transcript levels determined with standard protocols in peripheral blood and bone marrow for all time points with available data

  • Rate of MMR [ Time Frame: 3, 6, 9,12, 18,24, 36, 48, 66 ]
    Rate of MMR in newly diagnosed Ph+ CML CP and in Ph+ CML CP and AP patients resistant/intolerant to either imatinib or dasatnib by designated timepoints

  • Event Free Survival [ Time Frame: up to 66 cycles ]
    Event Free Survival is defined as the time from the date of first study drug intake to the first occurrence of any of the following loss of CHR, loss of MCyR ( PCyR + CCyR), progression to AP/BC (from CP) or to BC (from AP), or death from any cause. (Including events only during treatment)

  • Rate of Cytogenetic Response category [ Time Frame: 6, 12, 18, 24, 36, 48, 66 cycles ]
    Rate of cytogenetic response (complete, partial, major, minor, minimal and no response) in Ph+ CML-CP resistant/intolerant to imatinib or dasatinib by 6, 12, 18,24, 36, 48 and 66 cycles

  • Rate of CHR [ Time Frame: 3,6, 9, 12, 18, 24, 36, 48, 66 ]
    Rate of CHR in newly diagnosed Ph+ CML-CP and AP patients resistant/intolerant to either imatinib or dasatinib by designated timepoints

  • PK profile of nilotinib in pediatric patients [ Time Frame: up to 12 cycles ]
    Population PK parameters of nilotinib

  • Emerging signs of resistance [ Time Frame: up to 66 cycles ]
    Mutational assessment of BCR-ABL

  • Long term effect of nilotinib on growth, development and maturation [ Time Frame: up to 66 cycles ]
    Assessment of development (growth and sexual maturation) and thyroid function

  • Further characterize safety and tolerability [ Time Frame: up to 66 cycles ]
    Incidence and severity of adverse events, as assessed by patient symptoms, physical exam assessments, abnormal laboratory tests, echocardiograms and electrocardiograms

  • Acceptability of study drug formulation [ Time Frame: day1, day 28, early discontinuation or month 12 ]
    Questionnaire to capture patient assessment of palatability (very good to very bad) and acceptability of taking the medication (very easy to very hard to administration).


Other Outcome Measures:
  • Long term effect on nilotinib on bone metabolism [ Time Frame: up to 66 cycles ]
    Alteration of bone biochemical markers, DEXA and X-Ray


Estimated Enrollment: 70
Actual Study Start Date: August 20, 2013
Estimated Study Completion Date: October 7, 2020
Estimated Primary Completion Date: October 7, 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Newly diagnosed and untreated Ph+ CML in first chronic phase
Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.
Drug: nilotinib
Nilotinib will be administered at 230mg/m2 ,twice daily for up to 66 cycles (1 cycle = 28 days). Drug will be supplied in 50mg, 150mg,and 200mg capsules. Dose administration will be rounded to the nearest 50mg dose (to a maximum dose of 400mg).
Other Name: Tasigna, AMN107
Experimental: Resistant/intolerant Ph+ CML in chronic phase
Resistant or Intolerant to either imatnib or dasatnib
Drug: nilotinib
Nilotinib will be administered at 230mg/m2 ,twice daily for up to 66 cycles (1 cycle = 28 days). Drug will be supplied in 50mg, 150mg,and 200mg capsules. Dose administration will be rounded to the nearest 50mg dose (to a maximum dose of 400mg).
Other Name: Tasigna, AMN107
Experimental: Resistant/intolerant Ph+ CML in accelerated phase
Resistant or intolerant to either imatnib or dasatnib
Drug: nilotinib
Nilotinib will be administered at 230mg/m2 ,twice daily for up to 66 cycles (1 cycle = 28 days). Drug will be supplied in 50mg, 150mg,and 200mg capsules. Dose administration will be rounded to the nearest 50mg dose (to a maximum dose of 400mg).
Other Name: Tasigna, AMN107

  Eligibility

Ages Eligible for Study:   1 Year to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Newly diagnosed and untreated Ph+ CML CP or Ph+ CML CP or AP resistant or intolerant to either imatinib or dasatinib
  • Karnofsky or Lansky ≥ 50
  • Adequate renal, hepatic and pancreatic function
  • Potassium, magnesium, phosphorus and total calcium values ≥ LLN (lower limit of normal)
  • Written informed consent

Exclusion Criteria:

  • Treatment with strong CYP3A4 inhibitors or inducers
  • Use or planned use of any medications that have a known risk or possible risk to prolong the QT interval
  • Acute or chronic liver, pancreatic or severe renal disease
  • History of pancreatitis or chronic pancreatitis.
  • Impaired cardiac function
  • No evidence of active graft vs host and <3mo since Stem Cell Transplant
  • Total body irradiation (TBI) or craniospinal radiation therapy <6months
  • Hypersensitivity to the active ingredient or any of the excipients including lactose.
  • Other protocol-defined inclusion/exclusion criteria.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01844765

Contacts
Contact: Novartis Pharmaceuticals 1-888-669-6682 novartis.email@novartis.com
Contact: Novartis Pharmaceuticals +41613241111 novartis.email@novartis.com

  Show 88 Study Locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Children's Oncology Group
Innovative Therapies For Children with Cancer Consortium
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01844765     History of Changes
Other Study ID Numbers: CAMN107A2203
Study First Received: April 29, 2013
Last Updated: May 25, 2017
Individual Participant Data  
Plan to Share IPD: Undecided
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com


Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Tasigna
nilotinib treatment
chronic phase
Ph+ CML
accelerated phase
newly diagnosed Ph+ CML
pediatric
24 month treatment

Additional relevant MeSH terms:
Leukemia
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Myeloproliferative Disorders
Hematologic Diseases
Bone Marrow Diseases
Neoplastic Processes
Neoplasms by Histologic Type
Neoplasms
Pathologic Processes

ClinicalTrials.gov processed this record on June 28, 2017